ALT WOW! Feng Zhang’s new delivery company Aera Theraputics has presented in ASGCT 2026 new and promising preclinical data of its leading program AERA-109 - a targeted In Vivo CAR-T therapy designed to treat multiple B cell-mediated autoimmune diseases which uses Area’s proprietary and promising new delivery platform - targeted lipid nanoparticle (tLNP).

ALT Here is another ground breaking research from Prof. David Liu - from Harvard and broad institute and the co-founder of Beam and Prime medicine, in which a new directed evolution of structured RNA motifs that enhance the efficiency of prime editing was introduced . According to this new research a use of these motifs resulted in substantial Prime Editing efficiency gains, including at sites of pathogenic mutation in primary human stem cells and in immortalized human bronchial epithelial cells using different delivery methods. The importance of these new findings is that this could make Prime Editing-based Therapies much more effective.

ALT The excellent biospace shows the 5 biggest IPOs in BioTech history. At the top of this list is of course Kailera Therapeutics with its 625 million dollars blockbuster IPO - the largest public offering in recent years. The one that caught my eye is SANA which its 588 million dollars IPO was second only to Moderna.

ALT WOW! Allogene Therapeutics has just reported top tier clinical data from its Phase 2 ALPHA3 trial aimed to evaluate cema‑cel - Allogene’s allogeneic CD19 CAR T Cell Therapy for first-line (1L) consolidation in large B-cell lymphoma (LBCL) cancer. A huge milestone for allogeneic Cell Therapies!